Core Viewpoint - BGI Genomics plans to enhance its technology matrix through the acquisition of assets, aiming to solidify its position as a leading manufacturer in the life sciences sector by integrating cutting-edge technologies [1][4]. Group 1: Acquisition Details - BGI Genomics intends to acquire 100% equity of Sanjian Qifa and BGI Xifeng for a total cash consideration of 366 million yuan, which will incorporate two core technologies: spatial genomics and nanopore sequencing [2]. - The acquisition will enable BGI Genomics to establish a comprehensive technology ecosystem covering short-read, long-read, and spatial genomics, facilitating a one-stop service from library construction to sequencing and data analysis [2]. - The counterparties of the transaction have provided clear performance commitments, with Sanjian Qifa promising a cumulative net profit of no less than 50.1 million yuan from 2026 to 2028, and BGI Xifeng committing to a cumulative net profit of no less than 82.8 million yuan from 2028 to 2030 [2]. Group 2: Strategic Significance - The acquisition is expected to significantly reduce related-party transactions and resolve potential competition issues in the nanopore sequencing business, thereby enhancing the company's sustainable operational capabilities [2]. - Post-acquisition, BGI Genomics will achieve resource sharing and synergy in supply chain procurement, technology development, and customer service, which will serve as important growth engines for the company [2]. Group 3: Market Position and Performance - BGI Genomics has shown a notable improvement in its operational fundamentals, with a projected net loss of 221 million to 273 million yuan for 2025, representing a reduction in losses by approximately 60% compared to the previous year [3]. - The company secured 61% of the domestic high-throughput sequencing instrument market in 2025, with 232 units won in bids, demonstrating strong market penetration and customer recognition [3]. - BGI Genomics has been proactive in the AI pathology field since 2019, establishing the Spatial Pathology Alliance in 2025 and successfully registering its self-developed PMIF-20 pathology slide staining scanner, reinforcing its foundation for integrating AI with pathology analysis [3].